Management with Continence Products
CHAPTER 4 Committee 22 Management with Continence Products Chairman A. COTTENDEN (UK) Members D. BLISS (USA), M. FADER (UK), K. GETLIFFE (UK), H. HERRERA (USA) J. PATERSON (AUSTRALIA), G. SZONYI (AUSTRALIA), M. WILDE (USA), 149 CONTENTS A. PATIENT ASSESSMENT AND C. PRODUCTS FOR PRODUCT EVALUATION PREVENTING OR CONTAINING FAECAL INCONTINENCE B. PRODUCTS FOR PREVEN- TING OR CONTAINING URINARY INCONTINENCE D. OTHER CONTINENCE PRODUCT RELATED ISSUES 150 Management with Continence Products A. COTTENDEN D. BLISS, M. FADER, K. GETLIFFE, H. HERRERA, J. PATERSON, G. SZONYI, M. WILDE The product sections are preceded by two others: the A. PATIENT ASSESSMENT AND first provides overall guidelines for product selec- tion, while the second reviews the methodological PRODUCT EVALUATION challenges of conducting continence product evalua- tions and interpreting the results. I. INTRODUCTION II. PATIENT ASSESSMENT AND OVERALL GUIDELINES FOR Not all incontinence can be cured completely and SELECTING CONTINENCE even those who are successfully treated may have to PRODUCTS live with incontinence for a time while, for example, they wait for surgery or for pelvic floor muscle trai- Selecting suitable continence products is critical for ning to yield its benefits. Still others – depending on patient well-being. Ability to contain and conceal their frailty, severity of incontinence and personal incontinence enables individuals to protect their priorities – may not be candidates for treatment or public identity as a continent person and avoid the may choose management over attempted cure. For stigma associated with incontinence. Failure to do so all such people, the challenge is to discover how to can result in limited social and professional opportu- deal with their incontinence so as to minimise its nities, place relationships in jeopardy and detrimen- impact on their quality of life.
[Show full text]